These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
214 related articles for article (PubMed ID: 36894916)
41. PET monitoring of therapy response in head and neck squamous cell carcinoma. Schöder H; Fury M; Lee N; Kraus D J Nucl Med; 2009 May; 50 Suppl 1():74S-88S. PubMed ID: 19380408 [TBL] [Abstract][Full Text] [Related]
42. Multikinase inhibitors sorafenib and sunitinib as radiosensitizers in head and neck cancer cell lines. Affolter A; Samosny G; Heimes AS; Schneider J; Weichert W; Stenzinger A; Sommer K; Jensen A; Mayer A; Brenner W; Mann WJ; Brieger J Head Neck; 2017 Apr; 39(4):623-632. PubMed ID: 28221700 [TBL] [Abstract][Full Text] [Related]
43. Second-look PET-CT following an initial incomplete PET-CT response to (chemo)radiotherapy for head and neck squamous cell carcinoma. Prestwich RJD; Arunsingh M; Zhong J; Dyker KE; Vaidyanathan S; Scarsbrook AF Eur Radiol; 2020 Feb; 30(2):1212-1220. PubMed ID: 31485835 [TBL] [Abstract][Full Text] [Related]
44. Phase 1 study of EGFR-antisense DNA, cetuximab, and radiotherapy in head and neck cancer with preclinical correlatives. Bauman JE; Duvvuri U; Thomas S; Gooding WE; Clump DA; Karlovits B; Wehbe A; Miller FR; Kim S; Sen M; Heron DE; Grandis JR; Argiris A Cancer; 2018 Oct; 124(19):3881-3889. PubMed ID: 30291796 [TBL] [Abstract][Full Text] [Related]
45. The role of nanotherapy in head and neck squamous cell carcinoma by targeting tumor microenvironment. Zhang Y; Dong P; Yang L Front Immunol; 2023; 14():1189323. PubMed ID: 37292204 [TBL] [Abstract][Full Text] [Related]
46. Mast cell marker gene signature in head and neck squamous cell carcinoma. Cai Z; Tang B; Chen L; Lei W BMC Cancer; 2022 May; 22(1):577. PubMed ID: 35610596 [TBL] [Abstract][Full Text] [Related]
47. Patterns of Treatment Failure and Postrecurrence Outcomes Among Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma After Chemoradiotherapy Using Modern Radiation Techniques. Leeman JE; Li JG; Pei X; Venigalla P; Zumsteg ZS; Katsoulakis E; Lupovitch E; McBride SM; Tsai CJ; Boyle JO; Roman BR; Morris LGT; Dunn LA; Sherman EJ; Lee NY; Riaz N JAMA Oncol; 2017 Nov; 3(11):1487-1494. PubMed ID: 28542679 [TBL] [Abstract][Full Text] [Related]
48. [Immunocheckpoint inhibition in head and neck squamous cell carcinoma: the current status and progress]. Huang LL; Shi YK Zhonghua Zhong Liu Za Zhi; 2019 Sep; 41(9):641-647. PubMed ID: 31550852 [TBL] [Abstract][Full Text] [Related]
49. [Immunotherapy for head and neck squamous cell carcinoma]. Chen J; Chen M; Wu HT Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2017 Feb; 52(2):143-147. PubMed ID: 28219181 [TBL] [Abstract][Full Text] [Related]
50. Transcriptomic analysis reveals key lncRNAs associated with ribosomal biogenesis and epidermis differentiation in head and neck squamous cell carcinoma. Guo YZ; Sun HH; Wang XT; Wang MT J Zhejiang Univ Sci B; 2018 Sept.; 19(9):674-688. PubMed ID: 30178634 [TBL] [Abstract][Full Text] [Related]
51. Immunotherapy for Head and Neck Cancer. Sim F; Leidner R; Bell RB Hematol Oncol Clin North Am; 2019 Apr; 33(2):301-321. PubMed ID: 30833002 [TBL] [Abstract][Full Text] [Related]
52. Pretreatment ADC is not a prognostic factor for local recurrences in head and neck squamous cell carcinoma when clinical T-stage is known. Peltenburg B; Driessen JP; Vasmel JE; Pameijer FA; Janssen LM; Terhaard CHJ; de Bree R; Philippens MEP Eur Radiol; 2020 Feb; 30(2):1228-1231. PubMed ID: 31529258 [TBL] [Abstract][Full Text] [Related]
53. Cisplatin overcomes radiotherapy resistance in OCT4-expressing head and neck squamous cell carcinoma. Routila J; Qiao X; Weltner J; Rantala JK; Carpén T; Hagström J; Mäkitie A; Leivo I; Ruuskanen M; Söderlund J; Rintala M; Hietanen S; Irjala H; Minn H; Westermarck J; Ventelä S Oral Oncol; 2022 Apr; 127():105772. PubMed ID: 35245886 [TBL] [Abstract][Full Text] [Related]
54. Tumor Infiltrating Lymphocytes are Prognostic Factors and Can Be Markers of Sensitivity to Chemoradiotherapy in Head and Neck Squamous Cell Carcinoma. Suzuki H; Kawasaki Y; Miura M; Hatakeyama H; Shina K; Suzuki S; Yamada T; Suzuki M; Ito A; Omori Y Asian Pac J Cancer Prev; 2022 Apr; 23(4):1271-1278. PubMed ID: 35485685 [TBL] [Abstract][Full Text] [Related]
55. Human Mesenchymal Stromal Cells Do Not Cause Radioprotection of Head-and-Neck Squamous Cell Carcinoma. Rühle A; Lies M; Strack M; Perez RL; Bieber B; Thomsen AR; Bronsert P; Huber PE; Hess J; Knopf A; Wuchter P; Grosu AL; Nicolay NH Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887032 [TBL] [Abstract][Full Text] [Related]
56. Intratumoral therapies in head and neck squamous cell carcinoma: A systematic review and future perspectives. Jiménez-Labaig P; Rullan A; Braña I; Hernando-Calvo A; Moreno V; Doger B; Bitar G; Ap Dafydd D; Melcher A; Harrington KJ Cancer Treat Rev; 2024 Jun; 127():102746. PubMed ID: 38696902 [TBL] [Abstract][Full Text] [Related]
57. Wei Z; Shen Y; Zhou C; Cao Y; Deng H; Shen Z Bioengineered; 2022 May; 13(5):13784-13800. PubMed ID: 35712757 [TBL] [Abstract][Full Text] [Related]
58. Identification of factors related to immunotherapy efficacy and prognosis in patients with advanced head and neck squamous cell carcinoma. Xu X; Li R; Zhang L; Zhu G; Ren D; Wu L; Gong X Diagn Pathol; 2021 Nov; 16(1):110. PubMed ID: 34823553 [TBL] [Abstract][Full Text] [Related]
59. Glutathione S-transferase Polymorphisms in Head and Neck Squamous Cell Carcinoma Treated with Chemotherapy and/or Radiotherapy. Maniglia MP; Russo A; Biselli-Chicote PM; Oliveira-Cucolo JG; Rodrigues-Fleming GH; -Maniglia JV; Pavarino ÉC; Goloni-Bertollo EM Asian Pac J Cancer Prev; 2020 Jun; 21(6):1637-1644. PubMed ID: 32592358 [TBL] [Abstract][Full Text] [Related]
60. Co-expression network-based identification of biomarkers correlated with the lymph node metastasis of patients with head and neck squamous cell carcinoma. Jin Y; Qin X Biosci Rep; 2020 Feb; 40(2):. PubMed ID: 32076707 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]